Pacific Biosciences of California, Inc.
NASDAQ:PACBMedical - Devices
+$0.04 today
- Market cap
- $571.39M
- Beta
- 2.32
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.42
Volume 15.30M
Average 6.06M
PACB Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Pacific Biosciences of California, Inc.NASDAQ: PACB
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $6.1M, compared with -$4.12M a year earlier. Trailing-twelve-month accounts receivables was $2.3M.
Context
- Accounts receivables amounted to 5.0% of revenue in FY2025, down 1.0 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $6.1M or moves back toward the trailing-twelve-month quarterly average of $573.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (7.92M) USD
- Year-over-year change
- -187.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.92M) | -187.2% |
| FY2024 | 2024-12-31 | 9.09M | +151.0% |
| FY2023 | 2023-12-31 | (17.83M) | -426.8% |
| FY2022 | 2022-12-31 | 5.46M | +176.1% |
| FY2021 | 2021-12-31 | (7.17M) | — |
Accounts Receivables vs competitors
How PACB compares with its peers on the latest reported figures
- PACB's LTM Mar 2026 accounts receivables of $2.3M is the 2nd largest of the 3 companies compared; the peer median is $78.16M.
- Its year-over-year change of +273.6% is the highest of 3, against a peer median of +104.5%.
- Accounts receivables amounts to 1.4% of revenue for PACB, versus a peer median of 20.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $157M | +34.2% | +108.0% | 3.5% | |
| LTM Mar 2026 | $2.3M | +273.6% | — | 1.4% | |
| LTM Mar 2026 | $683K | +174.7% | — | 36.9% | |
| Peer median (excluding PACB) | $78.16M | +104.5% | +108.0% | 20.2% | |
Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (181.22M) | (314.25M) | (306.74M) | (309.85M) | (546.38M) |
| Depreciation & Amortization | 11.59M | 17.32M | 32.69M | 53.34M | 386.41M |
| Deferred Income Tax | (93.65M) | 0 | (11.42M) | (205K) | (546K) |
| Stock-Based Compensation | 80.73M | 78.61M | 0 | 0 | 41.67M |
| Change in Working Capital | 21.01M | (53.97M) | (58.96M) | (40.58M) | 4.44M |
| Accounts Receivables | (7.17M) | 5.46M | (17.83M) | 9.09M | (7.92M) |
| Inventory | (12.43M) | (33.91M) | (13.84M) | (8.32M) | (1.42M) |
| Accounts Payables | 6.36M | 1.03M | 206K | 1.41M | 2.48M |
| Other Working Capital | 34.24M | (26.55M) | (27.49M) | (42.75M) | 11.3M |
| Other Non-Cash Items | 50.37M | 9.08M | 77.88M | 91.24M | 3.19M |
| Operating Cash Flow | (111.18M) | (263.21M) | (266.55M) | (206.06M) | (111.21M) |
| Capital Expenditures | (5.93M) | (16.93M) | (8.84M) | (6.19M) | (2.71M) |
| Acquisitions (Net) | (319.79M) | 179K | (102K) | 0 | 0 |
| Purchases of Investments | (988.05M) | (442.79M) | (756.57M) | (498.64M) | (216.91M) |
| Sales of Investments | 635.24M | 575.8M | 770.12M | 628.83M | 340.07M |
| Other Investing Activities | 0 | (179K) | 0 | 0 | (5M) |
| Investing Cash Flow | (678.53M) | 116.08M | 4.6M | 124M | 115.45M |
| Debt Repayment | 895.18M | (1.61M) | (1.84M) | (50.69M) | 0 |
| Common Stock Issued | 294.85M | 11.23M | 204.52M | 7.7M | 3.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (20.44M) | 0 | (86.41M) | 0 | 0 |
| Financing Cash Flow | 1.17B | 9.62M | 116.27M | (42.99M) | 3.43M |
| Effect of Forex Changes | 0 | 0 | 500K | 890K | 0 |
| Net Change in Cash | 379.87M | (137.51M) | (145.18M) | (124.15M) | 7.67M |
| Free Cash Flow | (117.11M) | (280.14M) | (275.39M) | (212.25M) | (113.92M) |
Pacific Biosciences of California, Inc.
NASDAQ:PACB
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.